GSK GLAXOSMITHKLINE PLC ADRF SPONSORED ADR 1 ADR REP 2 ORD

Ownership history in Stanley-Laman Group, Ltd.  ·  24 quarters on record

AI Ownership Summary

Stanley-Laman Group, Ltd. reported GLAXOSMITHKLINE PLC ADRF SPONSORED ADR 1 ADR REP 2 ORD (GSK) in 24 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 0.75% in 2024 Q3. The latest visible filing shows GSK at 0.71% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this GSK ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Stanley-Laman Group, Ltd.'s position in GLAXOSMITHKLINE PLC ADRF SPONSORED ADR 1 ADR REP 2 ORD, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

GSK was reported at 0.71% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.75% in 2024 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Stanley-Laman Group, Ltd. held GSK — position size vs. price
% of Fund (quarterly)    GSK price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED 105,176 +1,040 +1.0% 0.71% $5.8M 2026-04-16 $57.13
2025 Q4 ADDED 104,136 +7,073 +7.3% 0.65% $5.1M 2026-01-23 $48.76
2025 Q3 REDUCED 97,063 -781 -0.8% 0.60% $4.2M 2025-10-22 $43.53
2025 Q2 REDUCED 97,844 -25,688 -20.8% 0.56% $3.8M 2025-07-29 $36.64
2025 Q1 ADDED 123,532 +16,313 +15.2% 0.74% $4.8M 2025-04-16 $34.01
2024 Q4 REDUCED 107,219 -23,241 -17.8% 0.51% $3.6M 2025-01-29 $33.35
2024 Q3 ADDED 130,460 +23,293 +21.7% 0.75% $5.3M 2024-10-22 $35.73
2024 Q2 ADDED 107,167 +97,578 +1017.6% 0.59% $4.1M 2024-07-18 $36.67
2024 Q1 UNCHANGED 9,589 0% 0.06% $411K 2024-04-17 $36.59
2023 Q4 REDUCED 9,589 -46,822 -83.0% 0.05% $355K 2024-02-02 $37.26
14 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

FAQ About Stanley-Laman Group, Ltd. and GSK

These are the practical questions this page is built to answer before you even open the full history table.

How long has Stanley-Laman Group, Ltd. reported owning GSK?

Stanley-Laman Group, Ltd. reported GSK across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported GSK position in Stanley-Laman Group, Ltd.'s portfolio?

The largest reported portfolio weight for GSK was 0.75% in 2024 Q3.

What is the latest reported GSK position on this page?

The most recent filing on this page is 2026 Q1, when Stanley-Laman Group, Ltd. reported 105,176 shares, equal to 0.71% of portfolio, with an estimated market value of $5.8M.

What does the chart on this GSK ownership page compare?

The chart compares Stanley-Laman Group, Ltd.'s quarterly GSK portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Stanley-Laman Group, Ltd. Holdings